Potential difficulties were identified regarding the respondents' comprehension of the questionnaire, which consisted of demographic items and multiple-choice questions regarding dental trauma and its management, and minor modifications were made according to these results.
Differences in AE management, specifically treatment dose modifications, were also observed in the Japanese subgroup.
Dose modifications were allowed for toxicity management in both treatments.
Dose modifications were allowed for toxicity management on both treatments.
For capecitabine, standard recommendations for dosage modifications were followed for the management of adverse events (AEs).
Standard recommendations for capecitabine dosage modifications were followed in the management of adverse events.
Some modifications were necessary.
Some lyrical modifications were made.
Another 764,340 trial modifications were ultimately rejected.
Modifications are made based on medical diagnoses and support symptom management.
